logo
  

FEI Names Anthony Trunzo EVP And CFO, Succeeding Raymond Link

FEI Company (FEIC) said that Anthony Trunzo has accepted an offer to join the company as its executive vice president and chief financial officer, effective April 10, 2015.

Trunzo will succeed Raymond Link, who is retiring after having served as FEI's EVP and CFO since July 2005, and as interim CEO and CFO from April 2006 to August 2006. Link will assist in transitioning his role to Trunzo.

Since 2010, Trunzo has been senior vice president, finance and CFO of FLIR Systems, Inc (FLIR), a maker of thermal imaging and other sensing products. He joined FLIR Systems in August 2003 as senior vice president, corporate strategy and development.

Prior to joining FLIR Systems, Trunzo was a managing director in the Investment Banking Group at Banc of America Securities, LLC, and previously held various positions at PNC Financial Services Group, Inc.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT